Journal of Bone Metabolism

"Hyung-keun Song"

Case Report

Atypical Femoral Fracture Combined with Osteonecrosis of Jaw During Osteoporosis Treatment with Bisphosphonate: Yougun Won, Joon-Ryul Lim, Young-Hwan Kim, Hyung-keun Song, Kyu Hyun Yang; J Bone Metab 2014;21(2):155-159.
Published online May 31, 2014; DOI: https://doi.org/10.11005/jbm.2014.21.2.155

Bisphosphonate, a potent anti-resorptive agent, is generally accepted as a safe, effective, well tolerated treatment for postmenopausal osteoporosis. Atypical femoral fracture (AFF) and bisphosphonate related osteonecrosis of jaw (BRONJ) are the increasing morbidities in patients treated with long term bisphosphonate. Pathogenic mechanisms of AFF and BRONJ are not fully identified and not identical. We report a case of BRONJ followed by AFF and its nonunion in a 67-year-old woman patient receiving an oral bisphosphonate during 7 years for the treatment of osteoporosis.

Citations

Citations to this article as recorded by

1. Gaps and alternative surgical and non-surgical approaches in the bone fragility management: an updated review
Umberto Tarantino, Ida Cariati, Chiara Greggi, Riccardo Iundusi, Elena Gasbarra, Giovanni Iolascon, Andreas Kurth, Kristina E. Akesson, Mary Bouxsein, Paolo Tranquilli Leali, Roberto Civinini, Francesco Falez, Maria Luisa Brandi
Osteoporosis International.2022; 33(12): 2467. CrossRef
2. Comprehensive Study of the Risk Factors for Medication-Related Osteonecrosis of the Jaw Based on the Japanese Adverse Drug Event Report Database
Shinya Toriumi, Akinobu Kobayashi, Yoshihiro Uesawa
Pharmaceuticals.2020; 13(12): 467. CrossRef
3. Prevalence and Risk Factors of Atypical Femoral Fracture Bone Scintigraphic Feature in Patients Experiencing Bisphosphonate-Related Osteonecrosis of the Jaw
Chang-Hee Lee, Seung Hyun Son, Chae Moon Hong, Ju Hye Jeong, Shin Young Jeong, Sang-Woo Lee, Jaetae Lee, Tae-Geon Kwon, Byeong-Cheol Ahn
Nuclear Medicine and Molecular Imaging.2018; 52(4): 311. CrossRef
4. Vitamin D supplementation: Hypothetical effect on medication-related osteonecrosis of the jaw
Alejandro I. Lorenzo-Pouso, Mario Pérez-Sayáns, Abel García, Javier Carballo
Medical Hypotheses.2018; 116: 79. CrossRef
5. Paget's Disease: Skeletal Manifestations and Effect of Bisphosphonates
Ho Kang, Young-Chang Park, Kyu Hyun Yang
Journal of Bone Metabolism.2017; 24(2): 97. CrossRef
6. Artemisia annua extract prevents ovariectomy-induced bone loss by blocking receptor activator of nuclear factor kappa-B ligand-induced differentiation of osteoclasts
Sun Kyoung Lee, Hyungkeun Kim, Junhee Park, Hyun-Jeong Kim, Ki Rim Kim, Seung Hwa Son, Kwang-Kyun Park, Won-Yoon Chung
Scientific Reports.2017;[Epub] CrossRef
7. Atypical femoral fractures related to bisphosphonate treatment
A. Koh, E. Guerado, P. V. Giannoudis
The Bone & Joint Journal.2017; 99-B(3): 295. CrossRef
8. Osteonecrosis of the jaw (ONJ) and atypical femoral fracture (AFF) in an osteoporotic patient chronically treated with bisphosphonates
A. Sánchez, R. Blanco
Osteoporosis International.2017; 28(3): 1145. CrossRef
9. Patients Receiving Parenteral Bisphosphonates for Malignant Disease and Having Developed an Atypical Femoral Fracture Are at Risk of Concomitant Osteonecrosis of the Jaw: An Evidence-Based Review
Lindsay L. Graves, Susan V. Bukata, Nona Aghazadehsanai, Tina I. Chang, Neal R. Garrett, Arthur H. Friedlander
Journal of Oral and Maxillofacial Surgery.2016; 74(12): 2403. CrossRef